probiotics

Global probiotic supplements in 2024: A $9.4B market, China’s surge, Europe’s e-commerce paradox, and fragmented regulation

Microbiomepost conducted an exclusive interview with George Paraskevakos, Executive Director at International Probiotic Association in order to discuss the global market of biotic products in 2025.

Why probiotic health claims rarely succeed at EFSA: evidence standards, study populations, and the challenge of live microorganisms

Ger T. Rijkers, University College Roosevelt, Netherlands, discusses the regulatory frame about probiotics in Europe.

Probiotics and public health: small interventions, billion-Euro stakes

Mike Holland, who has spent decades valuing the health and economic impacts of policy choices for the European Commission, the European Environment Agency and the OECD, discusses the economic impact…

Gut microbiome–immune system crosstalk: from homeostasis to strain-level opportunities

Three infant-derived strains isolated and developed by Coree srl that are potentially interesting for immune support.

Reinforcing the gut barrier: how probiotics support intestinal integrity and immune health

Arthur Ouwehand, Technical Fellow at IFF Finland, discusses the components and vulnerabilities of the gut barrier and reviews how probiotics and related dietary interventions can support its structure and function.

Probiotics and prevention: the €10 billion question for Europe

New IPA Europe analysis puts hard numbers on how evidence-based probiotic use could cut healthcare costs and boost productivity across the EU.

Bifidobacterium longum subsp. infantis M-63: shaping early-life gut microbiota and immunity in healthy full-term infants

Akari Hiraku, researcher at Innovative Research Institute, Morinaga Milk Industry Co., presented clinical data on Bifidobacterium longum subsp. infantis M-63, a probiotic strain with a remarkable capacity to utilize HMOs.

The story of three new probiotics: from infancy to discovery

Bifidobacterium breve 2TA, Lacticaseibacillus rhamnosus L13B, and Lactobacillus gasseri L6 are not just bacteria: they are witnesses to the intimate, ancestral dialogue between mothers, infants, and microbes.

Faecalibacterium prausnitzii: a microbiome-based candidate for IBD, C. diff and cancer

Philippe Langella, Research director at INRAE, talks about how F. prausnitzii could be a beneficial commensal.

Standardizing evidence on probiotics in acute gastroenteritis: why guidelines diverge and clinicians are confused

Yvan Vandenplas, Head of the Pediatric Hospital at the University Hospital Brussels, uses the example of probiotics in acute gastroenteritis to highlight how heterogeneous methodologies in evidence synthesis can lead…

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Scroll to Top